

1644

IT9



1600

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/583,200C

DATE: 07/02/2002  
TIME: 09:56:15

Input Set : A:\Substitute SeqList 2060\_0150002.txt  
Output Set: N:\CRF3\07022002\I583200C.raw

RECEIVED

JUL 08 2002

3 <110> APPLICANT: Fikes, John D.  
 4 Sette, Alessandro  
 5 Sidney, John  
 6 Southwood, Scott  
 7 Celis, Esteban  
 8 Keogh, Elissa A.  
 9 Chesnut, Robert  
 11 <120> TITLE OF INVENTION: HLA Class I A2 Tumor Associated Antigen  
 12 Peptides and Vaccine Compositions  
 15 <130> FILE REFERENCE: 2060.0150002  
 17 <140> CURRENT APPLICATION NUMBER: US 09/583,200C  
 C--> 18 <141> CURRENT FILING DATE: 2002-06-17  
 20 <150> PRIOR APPLICATION NUMBER: US 09/016,361  
 21 <151> PRIOR FILING DATE: 1998-01-30  
 23 <150> PRIOR APPLICATION NUMBER: US 60/036,696  
 24 <151> PRIOR FILING DATE: 1997-01-31  
 26 <160> NUMBER OF SEQ ID NOS: 57  
 28 <170> SOFTWARE: PatentIn version 3.1  
 30 <210> SEQ ID NO: 1  
 31 <211> LENGTH: 10  
 32 <212> TYPE: PRT  
 33 <213> ORGANISM: Artificial Sequence  
 35 <220> FEATURE:  
 36 <223> OTHER INFORMATION: CEA.233V10  
 38 <400> SEQUENCE: 1  
 39 Val Leu Tyr Gly Pro Asp Ala Pro Thr Val  
 40 1 5 10  
 42 <210> SEQ ID NO: 2  
 43 <211> LENGTH: 9  
 44 <212> TYPE: PRT  
 45 <213> ORGANISM: Artificial Sequence  
 47 <220> FEATURE:  
 48 <223> OTHER INFORMATION: CEA.605V9  
 50 <400> SEQUENCE: 2  
 51 Tyr Leu Ser Gly Ala Asn Leu Asn Val  
 52 1 5  
 54 <210> SEQ ID NO: 3  
 55 <211> LENGTH: 9  
 56 <212> TYPE: PRT  
 57 <213> ORGANISM: Artificial Sequence  
 59 <220> FEATURE:  
 60 <223> OTHER INFORMATION: CEA.687  
 62 <400> SEQUENCE: 3

P6 TECH CENTER 1600/2900

ENTERED

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/583,200C

DATE: 07/02/2002  
TIME: 09:56:15

Input Set : A:\Substitute SeqList 2060\_0150002.txt  
Output Set: N:\CRF3\07022002\I583200C.raw

63 Ala Thr Val Gly Ile Met Ile Gly Val  
64 1 5  
66 <210> SEQ ID NO: 4  
67 <211> LENGTH: 11  
68 <212> TYPE: PRT  
69 <213> ORGANISM: Artificial Sequence  
71 <220> FEATURE:  
72 <223> OTHER INFORMATION: p53.25V11  
74 <400> SEQUENCE: 4  
75 Leu Leu Pro Glu Asn Asn Val Leu Ser Pro Val  
76 1 5 10  
78 <210> SEQ ID NO: 5  
79 <211> LENGTH: 9  
80 <212> TYPE: PRT  
81 <213> ORGANISM: Artificial Sequence  
83 <220> FEATURE:  
84 <223> OTHER INFORMATION: p53.139L2  
86 <400> SEQUENCE: 5  
87 Lys Leu Cys Pro Val Gln Leu Trp Val  
88 1 5  
90 <210> SEQ ID NO: 6  
91 <211> LENGTH: 9  
92 <212> TYPE: PRT  
93 <213> ORGANISM: Artificial Sequence  
95 <220> FEATURE:  
96 <223> OTHER INFORMATION: p53.139L2B3  
98 <400> SEQUENCE: 6  
99 Lys Leu Asx Pro Val Gln Leu Trp Val  
100 1 5  
102 <210> SEQ ID NO: 7  
103 <211> LENGTH: 9  
104 <212> TYPE: PRT  
105 <213> ORGANISM: Artificial Sequence  
107 <220> FEATURE:  
108 <223> OTHER INFORMATION: p53.149L2  
110 <400> SEQUENCE: 7  
111 Ser Leu Pro Pro Pro Gly Thr Arg Val  
112 1 5  
114 <210> SEQ ID NO: 8  
115 <211> LENGTH: 9  
116 <212> TYPE: PRT  
117 <213> ORGANISM: Artificial Sequence  
119 <220> FEATURE:  
120 <223> OTHER INFORMATION: p53.149M2  
122 <400> SEQUENCE: 8  
123 Ser Met Pro Pro Pro Gly Thr Arg Val  
124 1 5  
126 <210> SEQ ID NO: 9  
127 <211> LENGTH: 9

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/583,200C

DATE: 07/02/2002  
TIME: 09:56:15

Input Set : A:\Substitute SeqList 2060\_0150002.txt  
Output Set: N:\CRF3\07022002\I583200C.raw

128 <212> TYPE: PRT  
129 <213> ORGANISM: Artificial Sequence  
131 <220> FEATURE:  
132 <223> OTHER INFORMATION: Her2/neu.369L2V9  
134 <400> SEQUENCE: 9  
135 Lys Leu Phe Gly Ser Leu Ala Phe Val  
136 1 5  
138 <210> SEQ ID NO: 10  
139 <211> LENGTH: 9  
140 <212> TYPE: PRT  
141 <213> ORGANISM: Artificial Sequence  
143 <220> FEATURE:  
144 <223> OTHER INFORMATION: Her2/neu.369V2V9  
146 <400> SEQUENCE: 10  
147 Lys Val Phe Gly Ser Leu Ala Phe Val  
148 1 5  
150 <210> SEQ ID NO: 11  
151 <211> LENGTH: 10  
152 <212> TYPE: PRT  
153 <213> ORGANISM: Artificial Sequence  
155 <220> FEATURE:  
156 <223> OTHER INFORMATION: Her2/neu.773  
158 <400> SEQUENCE: 11  
159 Val Met Ala Gly Val Gly Ser Pro Tyr Val  
160 1 5 10  
162 <210> SEQ ID NO: 12  
163 <211> LENGTH: 9  
164 <212> TYPE: PRT  
165 <213> ORGANISM: Artificial Sequence  
167 <220> FEATURE:  
168 <223> OTHER INFORMATION: Her2/neu.5  
170 <400> SEQUENCE: 12  
171 Ala Leu Cys Arg Trp Gly Leu Leu Leu  
172 1 5  
174 <210> SEQ ID NO: 13  
175 <211> LENGTH: 9  
176 <212> TYPE: PRT  
177 <213> ORGANISM: Artificial Sequence  
179 <220> FEATURE:  
180 <223> OTHER INFORMATION: MAGE3.271  
182 <400> SEQUENCE: 13  
183 Phe Leu Trp Gly Pro Arg Ala Leu Val  
184 1 5  
186 <210> SEQ ID NO: 14  
187 <211> LENGTH: 9  
188 <212> TYPE: PRT  
189 <213> ORGANISM: Artificial Sequence  
191 <220> FEATURE:  
192 <223> OTHER INFORMATION: Her2/neu.48

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/583,200C

DATE: 07/02/2002  
TIME: 09:56:15

Input Set : A:\Substitute SeqList 2060\_0150002.txt  
Output Set: N:\CRF3\07022002\I583200C.raw

194 <400> SEQUENCE: 14  
195 His Leu Tyr Gln Gly Cys Gln Val Val  
196 1 5  
198 <210> SEQ ID NO: 15  
199 <211> LENGTH: 9  
200 <212> TYPE: PRT  
201 <213> ORGANISM: Artificial Sequence  
203 <220> FEATURE:  
204 <223> OTHER INFORMATION: Her2/neu.435  
206 <400> SEQUENCE: 15  
207 Ile Leu His Asn Gly Ala Tyr Ser Leu  
208 1 5  
210 <210> SEQ ID NO: 16  
211 <211> LENGTH: 9  
212 <212> TYPE: PRT  
213 <213> ORGANISM: Artificial Sequence  
215 <220> FEATURE:  
216 <223> OTHER INFORMATION: CEA.691  
218 <400> SEQUENCE: 16  
219 Ile Met Ile Gly Val Leu Val Gly Val  
220 1 5  
222 <210> SEQ ID NO: 17  
223 <211> LENGTH: 9  
224 <212> TYPE: PRT  
225 <213> ORGANISM: Artificial Sequence  
227 <220> FEATURE:  
228 <223> OTHER INFORMATION: Her2/neu.369  
230 <400> SEQUENCE: 17  
231 Lys Ile Phe Gly Ser Leu Ala Phe Leu  
232 1 5  
234 <210> SEQ ID NO: 18  
235 <211> LENGTH: 9  
236 <212> TYPE: PRT  
237 <213> ORGANISM: Artificial Sequence  
239 <220> FEATURE:  
240 <223> OTHER INFORMATION: MAGE3.112  
242 <400> SEQUENCE: 18  
243 Lys Val Ala Glu Leu Val His Phe Leu  
244 1 5  
246 <210> SEQ ID NO: 19  
247 <211> LENGTH: 9  
248 <212> TYPE: PRT  
249 <213> ORGANISM: Artificial Sequence  
251 <220> FEATURE:  
252 <223> OTHER INFORMATION: CEA.24V9  
254 <400> SEQUENCE: 19  
255 Leu Leu Thr Phe Trp Asn Pro Pro Val  
256 1 5  
258 <210> SEQ ID NO: 20

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/583,200C

DATE: 07/02/2002  
TIME: 09:56:15

Input Set : A:\Substitute SeqList 2060\_0150002.txt  
Output Set: N:\CRF3\07022002\I583200C.raw

259 <211> LENGTH: 10  
260 <212> TYPE: PRT  
261 <213> ORGANISM: Artificial Sequence  
263 <220> FEATURE:  
264 <223> OTHER INFORMATION: MAGE3.160  
266 <400> SEQUENCE: 20  
267 Leu Val Phe Gly Ile Glu Leu Met Glu Val  
268 1 5 10  
270 <210> SEQ ID NO: 21  
271 <211> LENGTH: 11  
272 <212> TYPE: PRT  
273 <213> ORGANISM: Artificial Sequence  
275 <220> FEATURE:  
276 <223> OTHER INFORMATION: MAGE3.159  
278 <400> SEQUENCE: 21  
279 Gln Leu Val Phe Gly Ile Glu Leu Met Glu Val  
280 1 5 10  
282 <210> SEQ ID NO: 22  
283 <211> LENGTH: 9  
284 <212> TYPE: PRT  
285 <213> ORGANISM: Artificial Sequence  
287 <220> FEATURE:  
288 <223> OTHER INFORMATION: Her2/neu.689  
290 <400> SEQUENCE: 22  
291 Arg Leu Leu Gln Glu Thr Glu Leu Val  
292 1 5  
294 <210> SEQ ID NO: 23  
295 <211> LENGTH: 9  
296 <212> TYPE: PRT  
297 <213> ORGANISM: Artificial Sequence  
299 <220> FEATURE:  
300 <223> OTHER INFORMATION: Her2/neu.665  
302 <400> SEQUENCE: 23  
303 Val Val Leu Gly Val Val Phe Gly Ile  
304 1 5  
306 <210> SEQ ID NO: 24  
307 <211> LENGTH: 10  
308 <212> TYPE: PRT  
309 <213> ORGANISM: Artificial Sequence  
311 <220> FEATURE:  
312 <223> OTHER INFORMATION: MAGE2.157  
314 <400> SEQUENCE: 24  
315 Tyr Leu Gln Leu Val Phe Gly Ile Glu Val  
316 1 5 10  
318 <210> SEQ ID NO: 25  
319 <211> LENGTH: 10  
320 <212> TYPE: PRT  
321 <213> ORGANISM: Artificial Sequence  
323 <220> FEATURE:

RAW SEQUENCE LISTING ERROR SUMMARY  
PATENT APPLICATION: US/09/583,200C

DATE: 07/02/2002  
TIME: 09:56:16

Input Set : A:\Substitute SeqList 2060\_0150002.txt  
Output Set: N:\CRF3\07022002\I583200C.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:29; Xaa Pos. 3,7  
Seq#:30; Xaa Pos. 3  
Seq#:34; Xaa Pos. 3  
Seq#:37; Xaa Pos. 3  
Seq#:40; Xaa Pos. 3  
Seq#:56; Xaa Pos. 1,5,6,8,9  
Seq#:57; Xaa Pos. 1,3,5,6,7